- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AS-703569 | AS703569  | compound 2 [PMID: 22695126] | compound 60a [WO2005118544A2] | enantiomer E1 [WO2005118544A2] | R-763 | R763
Compound class: Synthetic organic
Comment: Cenisertib is an Aurora kinase A/B inhibitor that was developed for anti-cancer potential . We show the compound with chirality as specified by the IUPAC name submitted to the WHO for INN registration. It is compound 60a as claimed in patent WO2005118544A2 .
Cenisertib has improved aqueous solubility compared to the dual inhibitor ABT-348 (ilorasertib). Preclinical anti-proliferative efficacy of cenisertib has been demonstrated in a wide range of xenograft models  and cell lines .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|cenisertib (AS703569) has complted Phase 1 clinical evaluations in solid and hematological malignancies. Click here to link to the complete list of AS703569 trials registered at ClinicalTrials.gov.|